Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02839200 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
NCT02839200: Completed Phase 2 study, sponsored by Idorsia Pharmaceuticals.
NCT02839200 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 360 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02839200, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
Study Summary
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
Primary Outcome
WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)
Interventions
- DRUG Placebo 1
- DRUG Zolpidem
- DRUG ACT-541468 5 mg
- DRUG ACT-541468 10 mg
- DRUG ACT-541468 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2016-10-04 |
| Est. Completion | 2017-06-20 |
| Phase | Phase 2 |
What the finished NCT02839200 record still lists
NCT02839200 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (171% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo 1 is the first listed.
NCT02839200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02839200 about?
NCT02839200 is a clinical study titled "Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder". This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
What is the current status of trial NCT02839200?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2016-10-04. Estimated completion is 2017-06-20.
What interventions are being tested in trial NCT02839200?
The interventions under investigation include: Placebo 1 (DRUG), Zolpidem (DRUG), ACT-541468 5 mg (DRUG), ACT-541468 10 mg (DRUG), ACT-541468 25 mg (DRUG).
Who is sponsoring clinical trial NCT02839200?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02839200's enrollment target sits among peer trials
360 123rd of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI